Company: BIAF
Filing Date: 2025-05-02
Form Type: S-1
Source: 0001641172-25-008170
Chunk: 179

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-02
Form: S-1
Chunk 179
---
 Pre-Funded Warrant and us.

Placement Agent Warrants

We have also agreed to issue to the Placement Agent (or its designees) Placement Agent Warrants to purchase up to 210,420 shares of Common Stock, which equals 3.0% of the assumed aggregate number of shares of Common Stock and Pre-Funded Warrants sold in this offering,. The Placement Agent Warrants will have substantially the same terms as the April 2025 Warrants described above, including that they will have an exercise price of $[*] per share (representing 110% of the combined public offering price per share of Common Stock and accompanying April 2025 Warrant), except that the Placement Agent Warrants will not have any anti-dilution (other than protection against pro rata distributions or share combinations) provisions, will not include a provision to increase the number of shares underlying the Placement Agent Warrants upon the occurrence of a reverse stock split, will be immediately exercisable and will have a termination date that will be five years from the commencement of the sales pursuant to this offering. In accordance with FINRA Rule 5110(e), the Placement Agent may not sell, transfer, assign, pledge, or hypothecate the Placement Agent Warrant or the securities underlying such warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of such warrants or the underlying securities for a period of 180 days following the date of commencement of sales pursuant to this public offering. The Placement Agent Warrants are registered on the registration statement of which this prospectus is a part. The form of the Placement Agent Warrants is included as an exhibit to this registration statement of which this prospectus forms a part. See “Plan of Distribution” below.

| 84 |

<div align='center'>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES</div>

The following is a general discussion of the material U.S. federal income tax considerations applicable to the ownership and disposition of shares of our Common Stock and the Pre-Funded Warrants and April 2025 Warrants acquired in this offering. The Pre-Funded Warrants and the April 2025 Warrants are collectively referred to as, the “Warrants”). This discussion is for general information only and is not tax advice. Accordingly, all prospective holders of our Common Stock and Warrants should consult their own tax advisors with respect to the U.S. federal, state, local and non-U.S